Medical Specialty >> Pharmacy
Hints That Experimental Drug Might Curb a Form of ALS
1:15 PM CDT.
Read article
- Feds Warn of Home Carbon Monoxide Detectors That May Fail to Alarm
- Big Studies Test Effectiveness of Common Diabetes Meds
- Already Taking a Blood Thinner? Adding Aspirin May Do Harm
- FDA Warns of Cybersecurity Risk With Certain Medtronic Insulin Pumps
JOURNAL UPDATE
Total Number of HPV Vaccination Encounters Down During Pandemic
8:49 PM CDT.However, there was an increase seen in vaccinations per encounter, with seasonal variation
- Outcomes May Be Better for Warfarin Users Who Stop Aspirin Use
- Multidose Antibiotic Prophylaxis No Better for Breast Implant Surgery
- Unintentional Overdose Deaths in U.S. Teens Spiked in 2020
MONTHLY JOURNAL SUMMARY
September 2020 Briefing - Pharmacy
October 01, 2020. The Monthly Journal Summary is a single article covering the most important journal articles published in the previous 30 days.
FEATURED ARTICLES
Rucaparib Maintenance Therapy Improves PFS in Platinum-sensitive Ovarian Cancer - The ARIEL3 Trial
Robert L. Coleman, MD.
Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of…
Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
Ted Lain, MD.
Clinical trial investigator Dr. Ted Lain comments on the results of the OPAL study, a Phase 2b clinical trial which evaluated the efficacy of a novel topical gel formulation of the antibiotic minocycline (BPX-01) in reducing the number of inflammatory lesions in patients with moderate-to-severe inflammatory,…
Bevacizumab for breast cancer: FDA grants a stay of execution
Dr. Alberto De la Guerra.
The Food and Drug Administration has after repeated delays proposed removing metastatic breast cancer as an indication from the Avastin label. The proposal is being contested by Roche/Genentech, the drug’s maker. In this article we review the evidence for and against this decision.
MEDICAL FOCUS
DISCUSSION
RE: Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
By namabcAs I understand, this is a great step of development that we can use to save many people from horrible diseases. and i also hope Dr.Lain and your partners…
